Table 1
Open in new tab

Summarized clinical characteristics of BrS patients

SCN10ASCN5AP-value
Probands, n (%)857
Male, n (%)6 (75.0%)38 (66.7%)0.051
Age (years)0.074
 Mean ± SD49.7 ± 13.040.6 ± 11.4
 Min–Max34.1–72.516.6–67.5
Cardiac arrest/syncope, n (%)3 (37.5%)18 (31.6%)0.469
Spontaneous BrS ECG pattern0.244
 Type 1, n (%)4 (50.0%)16 (28.1%)
 Type 2, n (%)1 (12.5%)10 (17.5%)
 Type 3, n (%)3 (37.5%)31 (54.4%)
Family history of sudden death, n (%)3 (37.5%)17 (29.8%)0.982
Baseline substrate size (cm2)0.486
 Mean ± SD1.91 ± 4.543.11 ± 5.46
 Min–Max0.00–13.100.00–24.60
Substrate size after ajmaline (cm2)0.118
 Mean ± SD15.68 ± 4.4220.36 ± 9.26
 Min–Max9.90–24.202.20–44.10
Baseline potential duration (ms)0.352
 Mean ± SD106.11 ± 37.07113.54 ± 33.57
 Min–Max74.00–180.1064.40–187.40
Potential duration after ajmaline (ms)0.251
 Mean ± SD236.19 ± 10.76226.48 ± 20.85
 Min–Max210.20–241.20205.60–288.90
SCN10ASCN5AP-value
Probands, n (%)857
Male, n (%)6 (75.0%)38 (66.7%)0.051
Age (years)0.074
 Mean ± SD49.7 ± 13.040.6 ± 11.4
 Min–Max34.1–72.516.6–67.5
Cardiac arrest/syncope, n (%)3 (37.5%)18 (31.6%)0.469
Spontaneous BrS ECG pattern0.244
 Type 1, n (%)4 (50.0%)16 (28.1%)
 Type 2, n (%)1 (12.5%)10 (17.5%)
 Type 3, n (%)3 (37.5%)31 (54.4%)
Family history of sudden death, n (%)3 (37.5%)17 (29.8%)0.982
Baseline substrate size (cm2)0.486
 Mean ± SD1.91 ± 4.543.11 ± 5.46
 Min–Max0.00–13.100.00–24.60
Substrate size after ajmaline (cm2)0.118
 Mean ± SD15.68 ± 4.4220.36 ± 9.26
 Min–Max9.90–24.202.20–44.10
Baseline potential duration (ms)0.352
 Mean ± SD106.11 ± 37.07113.54 ± 33.57
 Min–Max74.00–180.1064.40–187.40
Potential duration after ajmaline (ms)0.251
 Mean ± SD236.19 ± 10.76226.48 ± 20.85
 Min–Max210.20–241.20205.60–288.90

Data were analysed by χ2 test or Mann–Whitney U test, where appropriate.

BrS, Brugada syndrome; ECG, electrocardiogram; SD, standard deviation.

Table 1
Open in new tab

Summarized clinical characteristics of BrS patients

SCN10ASCN5AP-value
Probands, n (%)857
Male, n (%)6 (75.0%)38 (66.7%)0.051
Age (years)0.074
 Mean ± SD49.7 ± 13.040.6 ± 11.4
 Min–Max34.1–72.516.6–67.5
Cardiac arrest/syncope, n (%)3 (37.5%)18 (31.6%)0.469
Spontaneous BrS ECG pattern0.244
 Type 1, n (%)4 (50.0%)16 (28.1%)
 Type 2, n (%)1 (12.5%)10 (17.5%)
 Type 3, n (%)3 (37.5%)31 (54.4%)
Family history of sudden death, n (%)3 (37.5%)17 (29.8%)0.982
Baseline substrate size (cm2)0.486
 Mean ± SD1.91 ± 4.543.11 ± 5.46
 Min–Max0.00–13.100.00–24.60
Substrate size after ajmaline (cm2)0.118
 Mean ± SD15.68 ± 4.4220.36 ± 9.26
 Min–Max9.90–24.202.20–44.10
Baseline potential duration (ms)0.352
 Mean ± SD106.11 ± 37.07113.54 ± 33.57
 Min–Max74.00–180.1064.40–187.40
Potential duration after ajmaline (ms)0.251
 Mean ± SD236.19 ± 10.76226.48 ± 20.85
 Min–Max210.20–241.20205.60–288.90
SCN10ASCN5AP-value
Probands, n (%)857
Male, n (%)6 (75.0%)38 (66.7%)0.051
Age (years)0.074
 Mean ± SD49.7 ± 13.040.6 ± 11.4
 Min–Max34.1–72.516.6–67.5
Cardiac arrest/syncope, n (%)3 (37.5%)18 (31.6%)0.469
Spontaneous BrS ECG pattern0.244
 Type 1, n (%)4 (50.0%)16 (28.1%)
 Type 2, n (%)1 (12.5%)10 (17.5%)
 Type 3, n (%)3 (37.5%)31 (54.4%)
Family history of sudden death, n (%)3 (37.5%)17 (29.8%)0.982
Baseline substrate size (cm2)0.486
 Mean ± SD1.91 ± 4.543.11 ± 5.46
 Min–Max0.00–13.100.00–24.60
Substrate size after ajmaline (cm2)0.118
 Mean ± SD15.68 ± 4.4220.36 ± 9.26
 Min–Max9.90–24.202.20–44.10
Baseline potential duration (ms)0.352
 Mean ± SD106.11 ± 37.07113.54 ± 33.57
 Min–Max74.00–180.1064.40–187.40
Potential duration after ajmaline (ms)0.251
 Mean ± SD236.19 ± 10.76226.48 ± 20.85
 Min–Max210.20–241.20205.60–288.90

Data were analysed by χ2 test or Mann–Whitney U test, where appropriate.

BrS, Brugada syndrome; ECG, electrocardiogram; SD, standard deviation.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close